Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
454 Corporation operates within the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 2 pending office actions. These matters are handled by 2 distinct examiners across 2 distinct art units. This indicates a diversified prosecution strategy with activity spread across different technical groups within the biotechnology field.
GUSSOW, ANNE is the busiest examiner, currently managing 1 busiest examiner pending office action. This examiner is part of the group of 2 distinct examiners involved in the company's current filings. Because each of the 2 pending office actions is in a different art unit, the practitioner must adapt to 2 distinct art units and their specific examination cultures.
Managing 2 pending office actions requires coordination across multiple examiners. GUSSOW, ANNE handles 1 busiest examiner pending action, while the other action is overseen by a different official. The involvement of 2 distinct examiners ensures that the portfolio's progress is not tied to the decisions of 1 individual. This variety of 2 distinct art units provides a broad base for the company's intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FONSECA LOPEZ, FRANCINI ALVARENGA | 1 | 28.6% | +30.0% |
| GUSSOW, ANNE | 1 | 57.9% | +43.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18309775 | PROCESSOR, COMPUTER READABLE MEDIUM AND/OR SOFTWARE FOR IDENTIFYING PROTECTED NUCLEOTIDES INCORPORATED IN SEQUENCING PRIMERS | FONSECA LOPEZ, FRANCINI ALVARENGA | — |
| 18309769 | PREPARING A SAMPLE FOR EVANESCENT WAVE IMAGING | GUSSOW, ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18309775 | PROCESSOR, COMPUTER READABLE MEDIUM AND/OR SOFTWARE FOR IDENTIFYING PROTECTED NUCLEOTIDES INCORPORATED IN SEQUENCING PRIMERS | FONSECA LOPEZ, FRANCINI ALVARENGA | — |
| 18309769 | PREPARING A SAMPLE FOR EVANESCENT WAVE IMAGING | GUSSOW, ANNE | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18309775 | PROCESSOR, COMPUTER READABLE MEDIUM AND/OR SOFTWARE FOR IDENTIFYING PROTECTED NUCLEOTIDES INCORPORATED IN SEQUENCING PRIMERS | FONSECA LOPEZ, FRANCINI ALVARENGA | 1685 | §101§103§112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18309769 | PREPARING A SAMPLE FOR EVANESCENT WAVE IMAGING | GUSSOW, ANNE | 1683 | §103§112 | Non-Final OA | — | Pending | Apr 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial454 Corporation has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Francini Alvarenga Fonseca Lopez has the most, with 1 of 454 Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
